# Ypsomed's YpsoMate autoinjector enters market with Terumo and Mylan

Ypsomed's YpsoMate autoinjector achieved its first commercial market entry, with Terumo Corporation filling its PLAJEX syringe with the drug Hulio (adalimumab) and assembling it with the YpsoMate. First commercial deliveries from Switzerland to Japan are completed.

- Type: Product launch
- Announced: 2018-12-07
- Where: Switzerland
- Status: completed
- Products: YpsoMate autoinjector, PLAJEX syringe, Hulio (adalimumab)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Terumo](https://endata.com/companies/2811.md) (customer)
- [Ypsomed](https://endata.com/companies/9625.md) (supplier)
- [Mylan N.V.](https://endata.com/companies/35955.md) (partner)
- [Fujifilm Kyowa Kirin Biologics Co., Ltd.](https://endata.com/companies/35956.md) (partner)

## Sources

- [ypsomed.com](https://www.ypsomed.com/en/news-insights/news/press-releases/news-reader-detail-page/first-market-entry-of-ypsomate-autoinjector-from-ypsomed), 2018-12-07: "For Ypsomed, this not only means the successful commercialisation of Hulio ® project launched in 2013, but also the first commercial market entry of the YpsoMate autoinjector."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.